Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2018-000100-41
    Sponsor's Protocol Code Number:PN018
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2018-08-07
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2018-000100-41
    A.3Full title of the trial
    A Randomized, Placebo-Controlled Study of ABX-1431 in Adult Patients with Tourette Syndrome or Chronic Motor Tic Disorder
    Estudio aleatorizado y controlado con placebo de ABX-1431 en pacientes adultos con Síndrome de Tourette o trastorno crónico de tic motor
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to investigate the experimental medication ABX-1431 in adult patients with tourette syndrome or chronic motor tic disorder
    Un estudio para investigar el medicamento experimental ABX 1431 en pacientes adultos con Síndrome de Tourette o trastorno crónico de tic motor
    A.3.2Name or abbreviated title of the trial where available
    Tourette Syndrome Titration Study
    Estudio de titulación del síndrome de Tourette
    A.4.1Sponsor's protocol code numberPN018
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAbide Therapeutics, Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAbide Therapeutics, Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationSERMES PLANIFICACION S.L
    B.5.2Functional name of contact pointUnidad de Puesta en Marcha
    B.5.3 Address:
    B.5.3.1Street AddressC/Rufino González 14, Esc.1ª-2ºD
    B.5.3.2Town/ cityMadrid
    B.5.3.3Post code28037
    B.5.3.4CountrySpain
    B.5.4Telephone number+3491375 69 30
    B.5.5Fax number+3491754 27 21
    B.5.6E-mailstart-up@sermescro.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameABX-1431
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNnot applicable
    D.3.9.2Current sponsor codeABX-1431 HCl
    D.3.9.3Other descriptive nameABX-1431; ABD-101131 HCl
    D.3.9.4EV Substance CodeSUB181701
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Tourette syndrome or chronic motor tic disorder
    Síndrome de Tourette o Transtorno de tics motores persistente
    E.1.1.1Medical condition in easily understood language
    Neuropsychiatric disorder characterized by multiple motor or vocal tics.
    Trastorno neuropsiquiátrico caracterizado por múltiples tics motores o vocales.
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10044127
    E.1.2Term Tourette's syndrome
    E.1.2System Organ Class 100000004850
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10009005
    E.1.2Term Chronic motor tic disorder
    E.1.2System Organ Class 100000004873
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To determine the efficacy of ABX-1431 in treating adult patients with TS or CMTD as measured by the change from baseline in Total Tic Score of the Yale Global Tic Severity Scale (YGTSS-TTS) compared with placebo.
    Determinar la eficacia de ABX-1431 para el tratamiento de pacientes adultos con ST o CMTD, medida por el cambio desde la situación inicial en el Total Tic Score de la Yale Global Tic Severity Scale (YGTSS-TTS), en comparación con el placebo.
    E.2.2Secondary objectives of the trial
    1. To determine the efficacy of ABX-1431 in treating adult patients with TS or CMTD as measured by the Adult Tic Questionnaires (ATQ), the Premonitory Urge for Tics Scale (PUTS), and the Clinical Global Impressions Scale for Improvement (CGI-I).

    2. To evaluate the safety of ABX-1431 in adult patients with TS or CMTD through the assessment of Adverse Events (AE), Serious Adverse Events (SAE), Serious Unexpected Serious Adverse Reactions (SUSAR) and discontinuations due to AE.
    1. Determinar la eficacia de ABX-1431 en el tratamiento del ST o CMTD en pacientes adultos, medida por los Adult Tic Questionnaires (ATQ), la Premonitory Urge for Tics Scale (PUTS) y la Clinical Global Impressions Scale for Improvement (CGI-I).

    2. Evaluar la seguridad de ABX-1431 en pacientes adultos con ST o CMTD por medio de la evaluación de los acontecimientos adversos (AA), acontecimientos adversos graves (AAG), sospecha de reacción adversa grave e imprevista (SUSAR) y suspensión del tratamiento por AA.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    The sub-study has no separate protocol, it is integrated into the protocol of the main study. The objectiveof the substudy is to collect additional pharmacokinetics data.
    El sub-estudio no tiene un protocolo separado, se integra en el protocolo del estudio principal. El objetivo del sub-estudio es recopilar datos farmacocinéticos adicionales.
    E.3Principal inclusion criteria
    a. Patient is a male or female ≥ 18 to 64 years of age at the Screening Visit.
    b. Patient has a diagnosis of TS or CMTD as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria.
    c. Patient’s YGTSS-TTS results must be ≥ 22 (range 0- 50) at the Baseline/Randomization Visit.
    d. At the Baseline/Randomization Visit patients must be taking a stable drug regimen for tics and comorbidities for 30 days and must be expected to remain on a stable drug regimen during this study. Patients receiving no medication for TS may participate. Patients who have recently discontinued medication for tics must have discontinued them for at least 30 days. For neuroleptic drugs (e.g. risperidone, aripiprazole), the minimum discontinuation period is 30 days prior to the Baseline/Randomization Visit. For injectable depot neuroleptic drugs the minimum discontinuation period is one dosage cycle plus 14 days.
    e. Patient is legally competent, has been informed of the nature and scope of relevance for the study, voluntarily agrees to participation, agrees to the study restrictions, and has signed the informed consent form (ICF) approved by the Ethics Review Committee (ERC).
    f. Patients using cannabinoid medications for their tics must discontinue their use at least 14 days prior to the Baseline/Randomization Visit. The Investigator and patient must be confident that these patients will not require these medications for the duration of the study until 14 days after the last dose of study medication. Examples of cannabinoids include cannabis in any form, nabilone or Δ9-tetrahydrocannabinol (THC)-containing medications such as nabiximols (Sativex®) or dronabinol. The use of recreational cannabinoids during this study is not permitted.
    g. Female patients of child-bearing potential must have a negative pregnancy test [serum or urine human chorionic gonadotropin (hCG)] at the Screening Visit and other indicated visits. They must practice a highly effective, reliable and medically approved contraceptive regimen during the study. Post-menopausal women may enter this study. Post-menopausal women are defined as those without menses in the past 12 months, and with a serum follicle stimulating hormone (FSH) in the post-menopausal range. Women who are surgically sterile may enter this study with written documentation of the surgical procedure.
    h. Male patients must be willing to use a condom with sexual partners during this study until 14 days after the last dose of study medication. Male patients must be willing to abstain from sperm donation for 3 months after the completion of this study.
    a. El paciente es un hombre o una mujer ≥ 18 a 64 años de edad en la visita de selección.
    b. El paciente tiene un diagnóstico de ST o CMTD según lo definido por los criterios del Manual diagnóstico y estadístico de trastornos mentales, quinta edición (DSM-5).
    c. Los resultados del paciente YGTSS-TTS deben ser ≥ 22 (intervalo 0-50) en la visita inicial/de aleatorización.
    d. En la visita inicial/de aleatorización, los pacientes deben estar tomando una farmacoterapia estable para los tics y las enfermedades concomitantes durante 30 días y deberán seguir una farmacoterapia estable durante el estudio. Pueden participar pacientes que no reciban medicación para el ST. Los pacientes que hayan suspendido recientemente la toma de la medicación para los tics, deben haberlo hecho como mínimo hace 30 días. Para los neurolépticos (p. ej., risperidona, aripiprazol), el período mínimo de suspensión son treinta días antes de la visita inicial/de aleatorización. Para los neurolépticos inyectables de acción prolongada, el período mínimo de interrupción es de un ciclo de dosificación más 14 días.
    e. El paciente está legalmente capacitado, ha sido informado sobre la naturaleza y el alcance de la importancia del estudio, acepta participar voluntariamente, acepta las limitaciones del estudio y ha firmado el formulario de consentimiento informado (FCI) aprobado por el Comité de Ética (CE).
    f. Los pacientes que usan medicamentos cannabinoides para tratar sus tics deberán dejar de usarlos al menos 14 días antes de la visita inicial/de aleatorización. El investigador y el paciente deben confiar en que estos pacientes no necesitarán estos medicamentos durante el estudio hasta 14 días después de la última dosis del medicamento del estudio. Cannabinoides son p. ej., el cannabis en cualquier forma, la nabilona o los medicamentos que contienen Δ9-tetrahidrocannabinol (THC) como nabiximols (Sativex®) o dronabinol. Durante el estudio no se permite el uso de cannabinoides recreativos.
    g. Pacientes mujeres con posibilidad de quedar embarazadas deben tener una prueba de embarazo negativa [gonadotropina coriónica humana (hCG) en suero u orina] en la visita de selección y en otras visitas indicadas. Durante el estudio deben tomar un tratamiento anticonceptivo altamente eficaz, fiable y médicamente aprobado. Pueden participar en este estudio las mujeres postmenopáusicas. "Mujeres postmenopáusicas" se definen como mujeres que no han tenido menstruaciones en los últimos 12 meses y presentan concentraciones de la hormona foliculoestimulante sérica (FSH) en el intervalo postmenopáusico. Las mujeres esterilizadas quirúrgicamente pueden participar en este estudio si presentan un certificado por escrito de la intervención quirúrgica.
    h. Los pacientes varones deben estar dispuestos a usar un preservativo con sus parejas sexuales durante este estudio hasta 14 días después de la última dosis del medicamento del estudio. Los pacientes varones no deben donar semen durante los 3 meses posteriores a la finalización de este estudio.
    E.4Principal exclusion criteria
    a. Patient is taking strong inducers or inhibitors of cytochrome P450 (CYP)3A4/5 or CYP2C9.
    b. Patient has evidence of alcohol abuse or dependence, as defined by the DSM-S criteria, with two or more of the 11 criteria at the Screening Visit or within 1 year before the Screening Visit.
    c. Patient has evidence of drug or chemical abuse (except nicotine), as defined by the DSM-5 criteria, at the Screening Visit or within 1 year before the Screening Visit.
    d. Patient is unwilling to comply with study restrictions including abstinence from cannabis and alcohol from the Baseline/Randomization Visit until the follow-up telephone call 14 days after the last dose of study medication.
    e. Patients receiving ongoing psychological therapy for tics such as Habit Reversal Training or Comprehensive Behavioral Intervention for Tics are excluded.
    f. Patient is a lactating or pregnant female, or a female who intends to become pregnant within 90 days following the last dose of study medication.
    g. Patient has one or more of the following laboratory results at the Screening Visit:
    - Aspartate transaminase (AST) > 3 x upper limit of normal (ULN)
    - Alanine transaminase (ALT) > 3 x ULN
    - Total bilirubin > 2 x ULN (unless due to Gilbert’s syndrome)
    h. Patient has an estimated creatinine clearance less than 60 mL/minute at the Screening Visit.
    i. Patient has a serum albumin level below the laboratory normal range at the Screening Visit, and the physician cannot rule out hepatic insufficiency based on consideration of clinical symptoms, clinical signs, and other laboratory tests.
    j. Patient has symptomatic chronic Hepatitis B and/or Hepatitis C Virus infection.
    k. Patient has a clinically significant abnormality on the ECG at the Screening Visit.
    l. Patients with a history of cancer will be excluded, with two exceptions: Patients with a history of squamous or basal cell carcinoma of the skin treated with documented success of curative therapy > 3 months may be enrolled.
    m. Patient has TS or CMTD and also has mental retardation, autism spectrum disorder (ASD), dystonia, or post-traumatic stress disorder (PTSD). Mental retardation may be defined by medical history. ASD and PTSD may be determined by medical history.
    n. Patient has confounding medical conditions such as active infection, primary or acquired immunodeficiency, uncontrolled diabetes, clinically significant cardiac disease, clinically significant renal disease, or any suspected hepatic insufficiency.
    o. Patient has a diagnosis of any psychiatric comorbidity such OCD, ADHD, anxiety disorder, and/or depression and has undergone a change in therapy in the 30 days before the Baseline/Randomization Visit or is in need of a change in treatment.
    p. Patient has a history of suicidal ideation with intent to act or a plan to act, or a suicide attempt in the last 3 years preceding the Baseline/Randomization Visit.
    q. Patient has participated in an investigational study for medications with the last visit within 1 month for a non-biologic agent and 90 days for a biologic agent of the Baseline/Randomization Visit.
    r. Patient is an employee of the investigative site or sponsor or a close relative of an employee of the investigative site.
    s. Patient has intolerance or hypersensitivity to the investigational medicinal product, ABX-1431 or the excipients.
    a. El paciente está tomando inductores o inhibidores potentes del citocromo P450 (CYP)3A4/5 o CYP2C9.
    b. Hay pruebas de que el paciente abusa o tiene dependencia del alcohol, según lo definido por los criterios del DSM-5, con dos o más de los 11 criterios en la visita de selección o en el año previo a la visita de selección.
    c. Hay pruebas de que el paciente abusa o tiene dependencia de medicamentos o sustancias químicas (excepto la nicotina) , según lo definido por los criterios del DSM-5 en la visita de selección o en el año previo a la visita de selección.
    d. El paciente no quiere cumplir con las limitaciones del estudio, como la abstinencia del consumo de cannabis y alcohol desde la visita inicial/de aleatorización hasta la llamada telefónica de seguimiento 14 días después de la última dosis del medicamento del estudio.
    e. Se excluyen los pacientes que reciben psicoterapia continua para sus tics, como la Terapia de reversión de hábitos o Intervención Global de Comportamiento para Tics.
    f. El paciente es una mujer que da el pecho o está embarazada o una mujer que está intentando quedarse embarazada en los 90 días tras la última dosis del medicamento del estudio.
    g. El paciente presenta en la visita de selección uno o varios de los siguientes resultados analíticos:
    -Aspartato-transaminasa (AST) > 3 veces el límite superior de la normalidad (LSN)
    -Alanina-transaminasa (ALT) > 3 veces LSN
    -Bilirrubina total > 2 veces LSN (excepto a causa del síndrome de Gilbert)
    h. El paciente tiene un aclaramiento de creatinina estimado inferior a 60 ml/minuto en la visita de selección.
    i. El paciente tiene una concentración de albúmina sérica por debajo del rango normal de laboratorio en la visita de selección, y el médico no puede descartar insuficiencia hepática considerando los síntomas clínicos, los signos clínicos y otras pruebas analíticas.
    j. El paciente tiene hepatitis B o hepatitis C crónica sintomática.
    k. El paciente presenta una anomalía clínicamente significativa en el electrocardiograma (ECG) en la visita de selección.
    l. Se excluirán los pacientes con antecedentes de cáncer, con dos excepciones: Se pueden incorporar pacientes con antecedentes de carcinoma epidermoide o basocelular de la piel con éxito documentado del tratamiento curativo > 3 meses.
    m. El paciente tiene ST o CMTD y y también un retraso mental, un trastorno del espectro autista (TEA), distonía o trastorno por estrés postraumático (TEPT). El retraso mental puede aparecer en la historia clínica. El TEA y el TEPT pueden aparecer en la historia clínica.
    n. El paciente presenta enfermedades confusas, como una infección activa, inmunodeficiencia primaria o adquirida, diabetes descontrolada, cardiopatía clínicamente significativa, nefropatía clínicamente significativa, o sospecha de insuficiencia hepática.
    o. El paciente ha sido diagnosticado de cualquier comorbilidad psiquiátrica como TOC, TDAH, trastorno de ansiedad o depresión, y se ha sometido a un cambio del tratamiento en los 30 días previos a la visita inicial/de aleatorización o requiere un cambio del tratamiento.
    p. El paciente tiene antecedentes de ideas de suicidio con decisión o un plan de actuar o ha tenido un intento de suicidio en los 3 años previos a la visita inicial/aleatorización.
    q. El paciente ha participado en un estudio de investigación de medicamentos con la última visita en el plazo de 1 mes para un fármaco no biológico y de 90 días para un fármaco biológico a partir de la visita inicial/de aleatorización.
    r. El paciente es un empleado del centro de investigación, del promotor o un pariente cercano de un empleado del centro de investigación.
    s. El paciente no tolera o es hipersensible al medicamento en investigación, al ABX-1431 o a sus excipientes.
    E.5 End points
    E.5.1Primary end point(s)
    Change from baseline in Total Tic Score of the Yale Global Tic Severity Scale (YGTSS-TTS) compared with placebo.
    Cambio desde la situación inicial en el Total Tic Score de la Yale Global Tic Severity Scale (YGTSS-TTS), en comparación con el placebo
    E.5.1.1Timepoint(s) of evaluation of this end point
    Day 56 (40 mg ABX-1431 per day) and Day 28 (20 mg ABX-1431 per day)
    Día 56 (40 mg ABX-1431 por día) y día 28 (20 mg ABX-1431 por día)
    E.5.2Secondary end point(s)
    Efficacy: Adult Tic Questionnaires (ATQ), the Premonitory Urge for Tics Scale (PUTS), Clinical Global Impressions Scale for Improvement (CGI-I).

    Safety: Adverse Events (AE), Serious Adverse Events (SAE), Serious Unexpected Serious Adverse Reactions (SUSAR), discontinuations due to AE.
    Eficacia: Adult Tic Questionnaires (ATQ), a Premonitory Urge for Tics Scale (PUTS), la Clinical Global Impressions Scale for Improvement (CGI-I)

    Seguridad: Acontecimientos adversos (AA), acontecimientos adversos graves (AAG), sospecha de reacción adversa grave e imprevista (SUSAR) y suspensión del tratamiento por AA
    E.5.2.1Timepoint(s) of evaluation of this end point
    Throughout the study
    A lo largo del estudio
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA9
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The trial ends with the last subject's last scheduled telephone call
    El ensayo finaliza con la última llamada telefónica programada del último sujeto
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months4
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months4
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 48
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state10
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 48
    F.4.2.2In the whole clinical trial 48
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    After their participation in the trial has ended, the subjects return to the normal treatment of their condition. No further treatment is provided within this protocol.
    Después de que su participación en el ensayo haya terminado, los sujetos vuelven al tratamiento normal de su condición. No se proporciona ningún tratamiento adicional dentro de este protocolo.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-11-21
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2018-08-27
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2020-01-14
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 05:14:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA